EJHaem · 2025
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma, Including Those Who are Triple-Class Exposed: A Retrospective Cohort Study in England Using National Cancer Registry Data.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsang Carmen, Arnold Kellyn, Duffield Charles, Oikonomou Stavros, Price Thomas, Mehdikhanova Tarana, Wood Samuel, Garg Mamta
Аннотация
INTRODUCTION: Multiple myeloma (MM) prognosis worsens once patients become triple-class exposed (TCE) to at least one treatment in each class: immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies.
METHODS: We conducted a retrospective study using the Cancer Analysis System database to assess characteristics, treatment patterns, and clinical outcomes for adults diagnosed with MM between 2014 and 2020. The main cohort included patients ≥18 years-old diagnosed with incident MM (including TCE patients) who had at least one record of systemic anticancer therapy treatment within 30 days prior to, on, or any time after their diagnosis.
RESULTS: The main cohort comprised 14,990 patients, predominantly white and male, with a median age at diagnosis of 71 years. Of these, 848 (5.6%) became TCE. In the main cohort (n = 14,990), 57.2% of patients received only one line of therapy, and >50% of all first-line regimens included bortezomib. Median overall survival (OS) from diagnosis was 51.5 months. After becoming TCE (n = 848), median OS was 13.2 months and median time to next treatment or death was 5.7 months.
CONCLUSIONS: This study provides current evidence on real-world OS and management for patients with MM in England, including those who become TCE.
METHODS: We conducted a retrospective study using the Cancer Analysis System database to assess characteristics, treatment patterns, and clinical outcomes for adults diagnosed with MM between 2014 and 2020. The main cohort included patients ≥18 years-old diagnosed with incident MM (including TCE patients) who had at least one record of systemic anticancer therapy treatment within 30 days prior to, on, or any time after their diagnosis.
RESULTS: The main cohort comprised 14,990 patients, predominantly white and male, with a median age at diagnosis of 71 years. Of these, 848 (5.6%) became TCE. In the main cohort (n = 14,990), 57.2% of patients received only one line of therapy, and >50% of all first-line regimens included bortezomib. Median overall survival (OS) from diagnosis was 51.5 months. After becoming TCE (n = 848), median OS was 13.2 months and median time to next treatment or death was 5.7 months.
CONCLUSIONS: This study provides current evidence on real-world OS and management for patients with MM in England, including those who become TCE.